Dusquetide for the Treatment of Behcet's Disease

Exclusion criteria

• ✕. Ten days prior to enrollment for mycophenolate mofetil
• ✕. Four weeks (28 days) prior to enrollment for cyclosporine, methotrexate, cyclophosphamide, thalidomide and dapsone
• ✕. Oral and topical corticosteroids must have been tapered as appropriate and discontinued 3 days prior to day of enrollment
• ✕. At least 5 terminal half-lives for all biologics including, but not limited to, those listed below; within: i. Four weeks prior to enrollment for etanercept; ii. Eight weeks prior to enrollment for infliximab; iii. Ten weeks prior to enrollment for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab; iv. Six months prior to enrollment for secukinumab.